23andMe Holding EBITDA 2021-2024 | MEHCQ
23andMe Holding ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
23andMe Holding Annual EBITDA
(Millions of US $) |
| 2024 |
$-300 |
| 2023 |
$-288 |
| 2022 |
$-228 |
| 2021 |
$-165 |
| 2020 |
$-1 |
| 2020 |
$-235 |
23andMe Holding Quarterly EBITDA
(Millions of US $) |
| 2024-12-31 |
$-31 |
| 2024-09-30 |
$-54 |
| 2024-06-30 |
$-66 |
| 2024-03-31 |
$-71 |
| 2023-12-31 |
$-57 |
| 2023-09-30 |
$-71 |
| 2023-06-30 |
$-101 |
| 2023-03-31 |
$-61 |
| 2022-12-31 |
$-88 |
| 2022-09-30 |
$-59 |
| 2022-06-30 |
$-80 |
| 2022-03-31 |
$-60 |
| 2021-12-31 |
$-89 |
| 2021-09-30 |
$-42 |
| 2021-06-30 |
$-37 |
| 2021-03-31 |
$91 |
| 2020-12-31 |
$-40 |
| 2020-09-30 |
$-31 |
| 2020-06-30 |
$-31 |
| 2020-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.220B |
|
23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.
|
